JPWO2019178296A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019178296A5
JPWO2019178296A5 JP2020548709A JP2020548709A JPWO2019178296A5 JP WO2019178296 A5 JPWO2019178296 A5 JP WO2019178296A5 JP 2020548709 A JP2020548709 A JP 2020548709A JP 2020548709 A JP2020548709 A JP 2020548709A JP WO2019178296 A5 JPWO2019178296 A5 JP WO2019178296A5
Authority
JP
Japan
Prior art keywords
cells
cell
reprogramming
aged
aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020548709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518331A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022149 external-priority patent/WO2019178296A1/en
Publication of JP2021518331A publication Critical patent/JP2021518331A/ja
Publication of JPWO2019178296A5 publication Critical patent/JPWO2019178296A5/ja
Priority to JP2023172587A priority Critical patent/JP2024016026A/ja
Pending legal-status Critical Current

Links

JP2020548709A 2018-03-13 2019-03-13 細胞加齢の反転のための一過性細胞リプログラミング Pending JP2021518331A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023172587A JP2024016026A (ja) 2018-03-13 2023-10-04 細胞加齢の反転のための一過性細胞リプログラミング

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642538P 2018-03-13 2018-03-13
US62/642,538 2018-03-13
PCT/US2019/022149 WO2019178296A1 (en) 2018-03-13 2019-03-13 Transient cellular reprogramming for reversal of cell aging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172587A Division JP2024016026A (ja) 2018-03-13 2023-10-04 細胞加齢の反転のための一過性細胞リプログラミング

Publications (2)

Publication Number Publication Date
JP2021518331A JP2021518331A (ja) 2021-08-02
JPWO2019178296A5 true JPWO2019178296A5 (zh) 2023-03-02

Family

ID=67907311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548709A Pending JP2021518331A (ja) 2018-03-13 2019-03-13 細胞加齢の反転のための一過性細胞リプログラミング
JP2023172587A Pending JP2024016026A (ja) 2018-03-13 2023-10-04 細胞加齢の反転のための一過性細胞リプログラミング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023172587A Pending JP2024016026A (ja) 2018-03-13 2023-10-04 細胞加齢の反転のための一過性細胞リプログラミング

Country Status (13)

Country Link
US (1) US20210010034A1 (zh)
EP (1) EP3764795A4 (zh)
JP (2) JP2021518331A (zh)
KR (1) KR20200131301A (zh)
CN (1) CN112154210A (zh)
AU (1) AU2019235861A1 (zh)
BR (1) BR112020018602A2 (zh)
CA (1) CA3093823A1 (zh)
CR (1) CR20200462A (zh)
IL (1) IL277265A (zh)
MX (1) MX2020009491A (zh)
SG (1) SG11202008839WA (zh)
WO (1) WO2019178296A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230091910A1 (en) * 2019-04-02 2023-03-23 Centagen, Inc. Engineered System of Stem Cell Rejuvenation to Treat Aging and Disease
JP2022544169A (ja) 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド 心血管疾患の処置および予防
TWI787761B (zh) * 2020-03-20 2022-12-21 台灣粒線體應用技術股份有限公司 粒線體用於促進傷口修復及/或傷口癒合之用途
WO2021211382A1 (en) * 2020-04-13 2021-10-21 Edifice Health, Inc. Compounds and methods for modifying iage
JP2023553815A (ja) * 2020-11-24 2023-12-26 ライエル・イミュノファーマ・インコーポレイテッド 幼若化したt細胞を作製する方法、それを含む組成物、及びその使用方法
WO2023288285A1 (en) 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Polycistronic expression vectors
WO2023061485A1 (zh) * 2021-10-14 2023-04-20 北京干细胞与再生医学研究院 年轻化骨骼肌肉细胞及其制备方法和应用
WO2023201097A1 (en) 2022-04-15 2023-10-19 Turn Biotechnologies, Inc. Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells
WO2023215857A2 (en) * 2022-05-06 2023-11-09 President And Fellows Of Harvard College Treatments for age-related cellular dysfunction
WO2024012503A1 (zh) * 2022-07-12 2024-01-18 南京瑞初医药有限公司 组合物及其使用方法
WO2024012502A1 (zh) * 2022-07-12 2024-01-18 南京瑞初医药有限公司 组合物及其使用方法
CN116426469B (zh) * 2023-06-07 2023-09-08 北京大学口腔医学院 LAP2α在间充质干细胞成脂向分化中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3611266B1 (en) * 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
US8669048B2 (en) * 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
PL3287525T3 (pl) * 2009-12-07 2020-05-18 The Trustees Of The University Of Pennsylvania Preparaty RNA zawierające oczyszczony zmodyfikowany RNA do przeprogramowywania komórek
US9057053B2 (en) * 2010-01-19 2015-06-16 The Board Of Trustees Of The Leland Stanford Junior University Direct conversion of cells to cells of other lineages
US8962331B2 (en) * 2010-02-01 2015-02-24 The Board Of Trustees Of The Leland Stanford Junior University Method of making induced pluripotent stem cell from adipose stem cells using minicircle DNA vectors
ES2695550T3 (es) * 2011-04-08 2019-01-09 Inst Nat Sante Rech Med Método para rejuvenecer células
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US9738873B2 (en) * 2014-02-10 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mRNA
EP3180443A1 (en) * 2014-08-13 2017-06-21 Timmons, James Archibald Healthcare diagnostic
WO2016112111A1 (en) * 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
WO2016115407A1 (en) * 2015-01-14 2016-07-21 Memorial Sloan-Kettering Cancer Center Age-modified cells and methods for making age-modified cells
EP3132809A1 (en) * 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
SG11202006160RA (en) * 2018-01-02 2020-07-29 Khloris Biosciences Inc Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
US20220162553A1 (en) * 2019-02-15 2022-05-26 The Board Of Trustees Of The Leland Stanford Junior University Generation of type 1 regulatory t cells through transcription factor targeting
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
US20230045590A1 (en) * 2019-12-23 2023-02-09 The Board Of Trustees Of The Leland Stanford Junior University Genetically corrected cells for therapeutic use

Similar Documents

Publication Publication Date Title
JP2021518331A (ja) 細胞加齢の反転のための一過性細胞リプログラミング
AU2022200207B2 (en) Compositions and methods for induced tissue regeneration in mammalian species
CN104937095B (zh) 肾细胞群及其用途
US20100135970A1 (en) Methods for Reprogramming Adult Somatic Cells and Uses Thereof
US20200199541A1 (en) Blood vessel organoid, methods of producing and using said organoids
CN102459576A (zh) 用于调节干细胞的组合物和方法及其应用
JPWO2019178296A5 (zh)
EP3835413A1 (en) Method and composition for promoting cell growth and tissue repair
CN109152799A (zh) 胰腺干细胞及其用途
Sarkar et al. Transient non-integrative nuclear reprogramming promotes multifaceted reversal of aging in human cells
RU2801316C2 (ru) Транзиентное клеточное перепрограммирование для обращения старения клетки
Kenigsberg et al. Genome engineering of human urine-derived stem cells to express lactoferrin and deoxyribonuclease
Shao et al. Human muscle stem/progenitor cells are bi-potential adult stem cells
Sarkar Transient Reprogramming for Multifaceted Reversal of Aging Phenotypes
US20110052551A1 (en) Cardiac myocyte morphogenic compositions and methods of use therefor
US20150056172A1 (en) Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling